LXRX - Lexicon Pharmaceuticals Inc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

552.5M

Cash

105.9M

Avg Qtr Burn

-24.26M

Short % of Float

6.98%

Insider Ownership

1.17%

Institutional Own.

81.33%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
XERMELO® (telotristat ethyl) Details Carcinoid syndrome diarrhea	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sotagliflozin (SGLT1/SGLT2) Details Heart disease, Heart failure Big Mover™ Suspected Mover™ Susp. Mover™	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sotagliflozin (Zynquista) (SGLT1/SGLT2) Details Type 1 diabetes, Diabetes	NDA Resubmission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LX9211 Details Neuropathy, Diabetic peripheral neuropathy, Postherpetic neuralgia	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.